246 related articles for article (PubMed ID: 32995922)
1. Prophylactic rituximab administration in children with complicated nephrotic syndrome.
Okutsu M; Kamei K; Sato M; Kanamori T; Nishi K; Ishiwa S; Ogura M; Sako M; Ito S; Ishikura K
Pediatr Nephrol; 2021 Mar; 36(3):611-619. PubMed ID: 32995922
[TBL] [Abstract][Full Text] [Related]
2. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
Kamei K; Ogura M; Sato M; Sako M; Iijima K; Ito S
Pediatr Nephrol; 2016 Jan; 31(1):89-95. PubMed ID: 26341251
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome.
Inoki Y; Kamei K; Nishi K; Sato M; Ogura M; Ishiguro A
Pediatr Nephrol; 2022 May; 37(5):1057-1066. PubMed ID: 34606002
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome.
Iijima K; Sako M; Oba M; Tanaka S; Hamada R; Sakai T; Ohwada Y; Ninchoji T; Yamamura T; Machida H; Shima Y; Tanaka R; Kaito H; Araki Y; Morohashi T; Kumagai N; Gotoh Y; Ikezumi Y; Kubota T; Kamei K; Fujita N; Ohtsuka Y; Okamoto T; Yamada T; Tanaka E; Shimizu M; Horinochi T; Konishi A; Omori T; Nakanishi K; Ishikura K; Ito S; Nakamura H; Nozu K;
J Am Soc Nephrol; 2022 Feb; 33(2):401-419. PubMed ID: 34880074
[TBL] [Abstract][Full Text] [Related]
8. Rituximab for nephrotic syndrome in children.
Iijima K; Sako M; Nozu K
Clin Exp Nephrol; 2017 Apr; 21(2):193-202. PubMed ID: 27422620
[TBL] [Abstract][Full Text] [Related]
9. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.
Ito S; Kamei K; Ogura M; Udagawa T; Fujinaga S; Saito M; Sako M; Iijima K
Pediatr Nephrol; 2013 Feb; 28(2):257-64. PubMed ID: 23052656
[TBL] [Abstract][Full Text] [Related]
10. Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective study.
Taşdemir M; Canpolat N; Yıldız N; Özçelik G; Benzer M; Saygılı SK; Özkayin EN; Türkkan ÖN; Balat A; Candan C; Çelakıl M; Yavuz S; Akıncı N; Göknar N; Akgün C; Tülpar S; Alpay H; Sever FL; Bilge İ
Turk J Med Sci; 2021 Aug; 51(4):1781-1790. PubMed ID: 33581711
[TBL] [Abstract][Full Text] [Related]
11. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial).
Nagano C; Sako M; Kamei K; Ishikura K; Nakamura H; Nakanishi K; Omori T; Nozu K; Iijima K
BMC Nephrol; 2019 Aug; 20(1):293. PubMed ID: 31375087
[TBL] [Abstract][Full Text] [Related]
12. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of discontinuing immunosuppression in children with idiopathic nephrotic syndrome.
Sobue Y; Nishi K; Kamei K; Inoki Y; Osaka K; Kaneda T; Akiyama M; Sato M; Ogura M; Ishikura K; Ishiguro A; Ito S
Pediatr Nephrol; 2024 Jun; 39(6):1825-1835. PubMed ID: 38270600
[TBL] [Abstract][Full Text] [Related]
14. Three-monthly bolus vitamin D supplements (1000 vs 400 IU/day) for prevention of bone loss in children with difficult-to-treat nephrotic syndrome: a randomised clinical trial.
Singh DN; Krishnamurthy S; Kamalanathan SK; Harichandrakumar KT; Sivamurukan P
Paediatr Int Child Health; 2018 Nov; 38(4):251-260. PubMed ID: 30092157
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotypic Alterations in Adult Patients with Steroid-Dependent and Frequently Relapsing Nephrotic Syndrome.
Casiraghi F; Todeschini M; Podestà MA; Mister M; Ruggiero B; Trillini M; Carrara C; Diadei O; Villa A; Benigni A; Remuzzi G
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175393
[TBL] [Abstract][Full Text] [Related]
16. Association between the time of initial relapse and subsequent relapses in patients with childhood-onset idiopathic nephrotic syndrome.
Inoki Y; Nishi K; Osaka K; Kaneda T; Akiyama M; Sato M; Ogura M; Kamei K
Pediatr Nephrol; 2024 Aug; 39(8):2393-2401. PubMed ID: 38267591
[TBL] [Abstract][Full Text] [Related]
17. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
Webb NJ; Woolley RL; Lambe T; Frew E; Brettell EA; Barsoum EN; Trompeter RS; Cummins C; Wheatley K; Ives NJ
Health Technol Assess; 2019 May; 23(26):1-108. PubMed ID: 31156083
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.
Lan L; Lin Y; Yu B; Wang Y; Pan H; Wang H; Lou X; Lang X; Zhang Q; Jin L; Yang Y; Xiao L; Chen J; Han F
Am J Nephrol; 2024; 55(1):25-36. PubMed ID: 37963441
[TBL] [Abstract][Full Text] [Related]
19. Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion.
Sato M; Kamei K; Ogura M; Ishikura K; Ito S
Clin Exp Nephrol; 2018 Feb; 22(1):110-116. PubMed ID: 28434126
[TBL] [Abstract][Full Text] [Related]
20. Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children.
Dossier C; Bonneric S; Baudouin V; Kwon T; Prim B; Cambier A; Couderc A; Moreau C; Deschenes G; Hogan J
Clin J Am Soc Nephrol; 2023 Dec; 18(12):1555-1562. PubMed ID: 37678236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
